Senior Director, Clinical Sciences
About this role
Company Overview
Tango Therapeutics is a biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer.
Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer.
This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing.
The Tango labs and offices are located at 201 Brookline Avenue, in the Fenway area of Boston, Massachusetts.
Summary
Tango has an exciting opportunity to join the team as our Senior Director, Clinical Sciences. This is a hands-on leadership role that combines functional leadership of the Clinical Science team with direct scientific leadership of one or more clinical development programs. The successful candidate will mentor and develop Clinical Scientists while remaining actively engaged in the design, execution, analysis, and interpretation of clinical studies. You will ensure scientific rigor throughout study conduct, oversee data review and analysis, and partner cross-functionally to advance clinical development programs. This role reports to the Vice President, Clinical Development.
Your Role:
- Lead, mentor, and develop a team of 4–6 Clinical Scientists, providing balanced resource allocation across Tango's clinical development portfolio
- Serve as a hands-on leader, combining people leadership with direct scientific leadership of one or more clinical program to ensure the successful design, execution, and interpretation of clinical studies
- Provide scientific leadership throughout the design, execution, analysis, and interpretation of early- and late-stage oncology clinical trials
- Partner closely with Clinical Development physicians, Clinical Operations, Biostatistics, Clinical Pharmacology, Pharmacovigilance, Regulatory Affairs, Translational Medicine, and Medical Writing to ensure high-quality execution of clinical programs
- Lead the development and review of key clinical documents, including protocols, investigator brochures, informed consent forms, clinical study reports, clinical development plans, and regulatory briefing materials.
- Interpret emerging clinical, safety, PK/PD, and biomarker data to inform study conduct, dose selection, expansion opportunities, and overall development strategy
- Contribute scientific expertise to regulatory submissions and health authority interactions
- Ensure consistency and excellence in Clinical Science deliverables by establishing best practices, mentoring team members, and continuously improving Clinical Science processes
- Represent Clinical Science on cross-functional study teams, governance committees, and portfolio discussions
- Foster a collaborative, accountable, and scientifically rigorous culture within the Clinical Science function
- Perform additional duties and responsibilities as required
What You Bring:
- MD, PhD, PharmD, MS within a relevant scientific discipline
- At least 12 years of experience in clinical science, or research
- At least 7 years of experience in oncology
- Demonstrated experience in designing and managing clinical trials, including knowledge of regulatory guidelines and GCP
- Strong analytical skills with proficiency in statistical analysis and interpretation of clinical data
- Excellent written and oral communication skills, with the ability to convey complex scientific concepts to diverse audiences
- Experience working in a fast-paced environment
We are an equal opportunity employer and value diversity at our company. We do not discriminate on the basis of race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability status.
Company at a glance
Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer.
Tango was launched in 2017 with a $55 million Series A investment from Third Rock Ventures. The company has established a robust product engine that leverages advances in DNA sequencing and CRISPR-based target discovery to generate breakthrough medicines that have the potential to provide deeper, more sustained benefit than today’s targeted therapies, and extend the benefit of available immuno-oncology agents.
Tango Therapeutics is focused on three areas of drug development, each in well-defined patient populations currently lacking effective treatment options, and each with hallmarks of cancer that have not been targeted yet. These include: loss of tumor suppressor gene function; multiple oncogenic drivers; and immune evasion.
What fuels each of Tango’s programs is an increasingly sophisticated ability to utilize synthetic lethality - the interaction between two genes that causes cell death when both are inactivated. In cancer cells, one of these genes is inactivated by mutation; the other will be inactivated by a drug. This approach leaves normal cells largely unaffected, with the potential to greatly enhance anti-tumor efficacy and reduce associated toxicity.
Tango’s success will be driven by its depth of understanding of the genetic subtypes of cancer, and corresponding insights into novel drug targets and combinations uniquely relevant to each subtype. By shaping discovery efforts in this way, Tango has the potential to reach the clinic quickly, and with a clear plan for identifying the patients most likely to benefit from each new treatment, an approach that could increase both speed and probability of success in translating novel target discoveries into transformational new medicines for patients.
Tired of cold applications?
Sign up with Clera and we'll reach out the moment a role actually fits you — no more spraying applications into the void.
Know someone who'd be great for this?